Searchable abstracts of presentations at key conferences in endocrinology

ea0029p245 | Calcium & Vitamin D metabolism | ICEECE2012

Vitamin D level and ALT level in Chinese-American patients with chronic hepaitits B in the new york city downtown area

Martell M. , Gao P. , Rincon-Bejarano L. , Chiu E. , Babbar R. , Mi L.

Background: Recent studies have suggested extensive associations between plasma levels of vitamin D and hepatobiliary diseases including viral hepatitis B or C. In hepatitis C, vitamin D deficiency may lead to a poor prognosis and a poor response to antiviral treatment. CHB has different pathophysiology. There has been no study on the association of vitamin D level and the ALT level in CHB patients, and it is not known whether vitamin D levels are associated with host response...

ea0029p1003 | Growth hormone IGF axis - basic | ICEECE2012

A new somavert (pegvisomant) 30 mg/ml formulation compared to the currently marketed 15 mg/ml formulation: pharmacokinetics, safety, and tolerability in healthy subjects

Jen J. , LaBadie R. , Liang Y. , Crownover P. , Gao X. , Hey-Hadavi J.

Introduction: Pegvisomant is indicated for acromegaly. Doses >20 mg are not commercially available, although daily doses up to 30 mg are approved.Objectives: 1. To estimate the relative bioavailability (relBA) of single-dose pegvisomant s.c. administrations, one injection of 30 mg/ml (1×30) vs two injections of 15 mg/ml (2×15), and 2. To evaluate their pharmacokinetics (PK), safety and tolerability.Methods: This was a...